The molecular era of surfactant biology

Neonatology

Volumn 105, Issue 4, 2014, Pages 337-343

  Whitsett, Jeffrey A ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Alveolar homeostasis; Lung diseases; Surfactant biology

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LUNG SURFACTANT; TELOMERASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXF1; TRANSCRIPTION FACTOR NKX2 1; UNCLASSIFIED DRUG; SURFACTANT ASSOCIATED PROTEIN; SURFACTANT; THYROID TRANSCRIPTION FACTOR 1;

ACUTE DISEASE; ACUTE LUNG DISEASE; ADULT DISEASE; CHRONIC LUNG DISEASE; CLEARANCE; CONFERENCE PAPER; GENE MUTATION; HOMEOSTASIS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS PROTEINOSIS; LUNG CAPILLARY; LUNG DISEASE; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSIS; MORPHOGENESIS; NEWBORN DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RESPIRATORY FAILURE; ADULT; AGE; ANIMAL; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; INFANT, NEWBORN, DISEASES; LUNG; LUNG DISEASES; METABOLISM; MUTATION; NEWBORN; PATHOPHYSIOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; DYSPLASIA; LUNG ALVEOLUS EPITHELIUM CELL;

ADULT; AGE FACTORS; ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HOMEOSTASIS; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LUNG; LUNG DISEASES; MUTATION; PHENOTYPE; PULMONARY SURFACTANT-ASSOCIATED PROTEINS; PULMONARY SURFACTANTS; SIGNAL TRANSDUCTION;

EID: 84902476593     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000360649     Document Type: Conference Paper

References (72)

1. Avery ME, Mead J: Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959; 97: 517-523.
2. Enhorning G, Robertson B: Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant. Pediatrics 1972; 50: 58-66.
3. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T: Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980; 1: 55-59.
4. Yu S, Harding PG, Smith N, Possmayer F: Bovine pulmonary surfactant: chemical composition and physical properties. Lipids 1983; 18: 522-529.
5. Egberts J, de Winter JP, Sedin G, de Kleine MJ, Broberger U, van Bel F, Curstedt T, Robertson B: Comparison of prophylaxis and rescue treatment with Curosurf in neonates less than 30 weeks gestation: a randomized trial. Pediatrics 1993; 92: 768-774.
6. Stevens TP, Harrington EW, Blennow M, Soll RF: Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2007; 4:CD003063.
7. Whitsett JA, Hull WM, Ohning B, Ross G, Weaver TE: Immunologic identification of a pulmonary surfactant-associated protein of molecular weight = 6000 daltons. Pediatr Res 1986; 20: 744-749.
8. Whitsett JA, Ohning BL, Ross G, Meuth J, Weaver T, Holm BA, Shapiro DL, Notter RH: Hydrophobic surfactant-associated protein in whole lung surfactant and its importance for biophysical activity in lung surfactant extracts used for replacement therapy. Pediatr Res 1986; 20: 460-467.
9. Notter RH, Shapiro DL, Ohning B, Whitsett JA: Biophysical activity of synthetic phospholipids combined with purified lung surfactant 6000 dalton apoprotein. Chem Phys Lipids 1987; 44: 1-17.
10. Rider ED, Ikegami M, Whitsett JA, Hull W, Absolom D, Jobe AH: Treatment responses to surfactants containing natural surfactant proteins in preterm rabbits. Am Rev Respir Dis 1993; 147: 669-676.
11. Whitsett JA, Wert SE, Weaver TE: Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med 2010; 61: 105-119.
12. Whitsett JA, Weaver TE: Hydrophobic surfactant proteins in lung function and disease. N Engl J Med 2002; 347: 2141-2148.
13. McCormack FX, Whitsett JA: The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest 2002; 109: 707-712.
14. Ariki S, Nishitani C, Kuroki Y: Diverse functions of pulmonary collectins in host defense of the lung. J Biomed Biotechnol 2012; 2012: 532071.
15. Perez-Gil J, Weaver TE: Pulmonary surfactant pathophysiology: current models and open questions. Physiology 2010; 25: 132-141.
16. Curstedt T, Calkovska A, Johansson J: New generation synthetic surfactants. Neonatology 2013; 103: 327-330.
17. Kurland G, Deterding RR, Hagood JS, Young LR, Brody, AS, Castile RG, Dell S, et al; American Thoracic Society Committee on Childhood Interstitial Lung Disease and the Child Research Network: An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy. Am J Respir Crit Care Med 2013; 188: 376-394.
18. Wert SE, Whitsett JA, Nogee LM: Genetic disorders of surfactant dysfunction. Pediatr Dev Pathol 2009; 12: 253-274.
19. Nogee LM, Garnier G, Dietz HC, Singer L, Murphy AM, deMello DE, Colten HR: A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994; 93: 1860-1863.
20. Clark JC, Wert SE, Bachurski CJ, Stahlman MT, Stripp BR, Weaver TE, Whitsett JA: Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc Natl Acad Sci USA 1995; 92: 7794-7798.
21. Melton KR, Nesslein LL, Ikegami M, Tichelaar JW, Clark JC, Whitsett JA, Weaver TE: SP-B deficiency causes respiratory failure in adult mice. Am J Physiol Lung Cell Mol Physiol 2003; 285:L543-L549.
22. Nogee LM, Wert SE, Proffit SA, Hull WM, Whitsett JA: Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency. Am J Respir Crit Care Med 2000; 161: 973-981.
23. Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M: ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 2004; 350: 1296-1303.
24. Hayes D Jr, Lloyd EA, Fitch JA, Bush A: ABCA3 transporter deficiency. Am J Respir Crit Care Med 2012; 186: 807.
25. Bohinski RJ, Di Lauro R, Whitsett JA: The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis. Mol Cell Biol 1994; 14: 5671-5681.
26. Kimura S, Hara Y, Pineau T, Fernandez-Salguero P, Fox CH, Ward JM, Gonzalez FJ: The T/ebp null mouse: thyroid-specific enhancerbinding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev 1996; 10: 60-69.
27. DeFelice M, Silberschmidt D, DiLauro R, Xu Y, Wert SE, Weaver TE, Bachurski CJ, Clark JC, Whitsett JA: TTF-1 phosphorylation is required for peripheral lung morphogenesis, perinatal survival, and tissue-specific gene expression. J Biol Chem 2003; 278: 35574-35583.
28. Guillot L, Carre A, Szinnai G, Castanet M, Tron E, Jaubert F, Broutin I, Counil F, Feldmann D, Clement A, Polak M, Epaud R: NKX2-1 mutations leading to surfactant protein promoter dysregulation cause interstitial lung disease in Brain-Lung-Thyroid Syndrome. Hum Mutat 2010; 31:E1146-E1162.
29. Hamvas A, Deterding RR, Wert SE, White FV, Dishop MK, Alfano DN, Halbower AC, et al: Heterogeneous pulmonary phenotypes associated with mutations in the thyroid transcription factor gene NKX2-1. Chest 2013; 144: 794-804.
30. Young LR, Deutsch GH, Bokulic RE, Brody AS, Nogee LM: A mutation in TTF1/NKX2.1 is associated with familial neuroendocrine cell hyperplasia of infancy. Chest 2013; 144: 1199-1206.
31. Alameh J, Bachiri A, Devisme L, Truffert P, Rakza TR, Riou Y, Manouvrier S, Lequien P, Storme L: Alveolar capillary dysplasia: a cause of persistent pulmonary hypertension of the newborn. Eur J Pediatr 2002; 161: 262-266.
32. Kalinichenko VV, Lim L, Stolz DB, Shin B, Rausa FM, Clark J, Whitsett JA, Watkins SC, Costa RH: Defects in pulmonary vasculature and perinatal lung hemorrhage in mice heterozygous null for the Forkhead Box f1 transcription factor. Dev Biol 2001; 235: 489-506.
33. Stankiewicz P, Sen P, Bhatt SS, Storer M, Xia Z, Beijani BA, Ou Z, et al: Genomic and genic deletions of the FOX gene cluster on 16q24.1 and inactivating mutations of FOXF1 cause alveolar capillary dysplasia and other malformations. Am J Hum Genet 2009; 84: 780-791.
34. Kalin TV, Meliton L, Meliton AY, Zhu X, Whitsett JA, Kalinichenko VV: Pulmonary mastocytosis and enhanced lung inflammation in mice heterozygous null for the FOXF1 gene. Am J Respir Cell Mol Biol 2008; 39: 390-399.
35. Vorbroker DK, Voorhout WF, Weaver TE, Whitsett JA: Posttranslational processing of surfactant protein C in rat type II cells. Am J Physiol 1995; 269:L727-L733.
36. Glasser SW, Detmer EA, Ikegami M, Na CL, Stahlman MT, Whitsett JA: Pneumonitis and emphysema in sp-C gene targeted mice. J Biol Chem 2003; 278: 14291-14298.
37. Glasser SW, Senft AP, Whitsett JA, Maxfield MD, Ross GF, Richardson TR, Prows DR, Xu Y, Korfhagen TR: Macrophage dysfunction and susceptibility to pulmonary Pseudomonas aeruginosa infection in surfactant protein C-deficient mice. J Immunol 2008; 181: 621-628.
38. Glasser SW, Maxfield MD, Ruetschilling TL, Akinbi HT, Baatz JE, Kitzmiller JA, Page K, Xu Y, Bao EL, Korfhagen TR: Persistence of LPS-induced lung inflammation in surfactant protein-C-deficient mice. Am J Respir Cell Mol Biol 2013; 49: 845-854.
39. Willander H, Askarieh G, Landreh M, Westermark P, Nordling K, Keranen H, Hermansson E, et al: High-resolution structure of a BRICHOS domain and its implications for anti-amyloid chaperone activity on lung surfactant protein C. Proc Natl Acad Sci USA 2012; 109: 2325-2329.
40. Nogee LM, Dunbar AE, 3rd, Wert SE, Askin F, Hamvas A, Whitsett JA: A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344: 573-579.
41. Bridges JP, Xu, Y, Na, CL, Wong HR, Weaver TE: Adaptation and increased susceptibility to infection associated with constitutive expression of misfolded SP-C. J Cell Biol 2006; 172: 395-407.
42. Woischnik M, Sparr C, Kern S, Thurm T, Hector A, Hartl D, Liebisch G, et al: A non-BRICHOS surfactant protein c mutation disrupts epithelial cell function and intercellular signaling. BMC Cell Biol 2010; 11: 88.
43. Thomas AQ, Lane K, Phillips J 3rd, Prince M, Markin C, Speer M, Schwartz DA, et al: Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002; 165: 1322-1328.
44. Lawson WE, Grant SW, Ambrosini V, Ambrosini V, Womble KE, Dawson EP, Lane KB, et al: Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax 2004; 59: 977-980.
45. Kingma PS, Whitsett JA: In defense of the lung: surfactant protein A and surfactant protein D. Curr Opin Pharmacol 2006; 6: 277-283.
46. Korfhagen TR, Bruno MD, Ross GF, Huelsman KM, Ikegami M, Jobe AH, Wert SE, et al: Altered surfactant function and structure in SP-A gene targeted mice. Proc Natl Acad Sci USA 1996; 93: 9594-9599.
47. Garcia CK: Idiopathic pulmonary fibrosis: update on genetic discoveries. Proc Am Thorac Soc 2011; 8: 158-162.
48. Maitra M, Dey M, Yuan WC, Nathanielsz PW, Garcia CK: Lung fibrosis-associated surfactant protein A1 and C variants induce latent transforming growth factor beta1 secretion in lung epithelial cells. J Biol Chem 2013; 288: 27159-27171.
49. Iniesta P, Gonzalez-Quevedo R, Moran A, Garcia-Aranda C, de Juan C, Sanchez-Permaute A, Torres A, Diaz-Rubio E, Balibrea JL, Benito M: Relationship between 3p deletions and telomerase activity in non-small-cell lung cancer: prognostic implications. Br J Cancer 2004; 90: 1983-1988.
50. Devine MS, Garcia CK: Genetic interstitial lung disease. Clin Chest Med 2012; 33: 95-110.
51. Brennan P, Hainaut P, Boffetta P: Genetics of lung-cancer susceptibility. Lancet Oncol 2011; 12: 399-408.
52. Todd DA, Marsh MJ, George A, Henderson NG, Barr H, Sebastian S, Clark GT, Koster G, Clark HW, Postle AD: Surfactant phospholipids, surfactant proteins, and inflammatory markers during acute lung injury in children. Pediatr Crit Care Med 2010; 11: 82-91.
53. Ichiyasu H, Ichikado K, Yamashita A, Iyonaga K, Sakamoto O, Suga M, Kohrogi H: Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in nonspecific interstitial pneumonia. Respiration 2012; 83: 190-197.
54. Zhang Y, Kaminski N: Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2012; 18: 441-446.
55. Ishikawa T, Kubota T, Abe H, Hirose K, Nagashima A, Togashi T, Seki K, Honma T, Yoshida T, Kamimura T: Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C. Hepatogastroenterology 2012; 59: 2260-2263.
56. Bowler RP: Surfactant protein D as a biomarker for chronic obstructive pulmonary disease. COPD 2012; 9: 651-653.
57. Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, Abe S: Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995; 152: 1860-1866.
58. Trapnell BC, Whitsett JA, Nakata K: Pulmonary alveolar proteinosis. N Engl J Med 2003; 349: 2527-2539.
59. Kitamura T, Tanaka N, Watanabe J, Uchida, Kanegaski S, Yamada Y, Nakata K: Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colonystimulating factor. J Exp Med 1999; 190: 875-880.
60. Suzuki T, Maranda B, Sakagami T, Catellier P, Couture CY, Carey BC, Chalk C, Trapnell BC: Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mutations. Eur Respir J 2011; 37: 201-204.
61. Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, Zimmerman SL, Smolarek T, et al: Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 2008; 205: 2703-2710.
62. Tanaka T, Motoi N, Tsuchihashi Y, Tazawa R, Kaneko C, Nei T, Yamamoto T, et al: Adultonset hereditary pulmonary alveolar proteinosis caused by a single-base deletion in CSF2RB. J Med Genet 2011; 48: 205-209.
63. Uchida K, Nakata K, Carey B, Chalk C, Suzuki T, Sakagami T, Koch DE, et al: Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. J Immunol Methods 2014; 402: 57-70.
64. Suzuki T, Mayhew C, Sallese A, Chalk C, Carey BC, Malik P, Wood RE, Trapnell BC: Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis. Am J Respir Crit Care Med 2014; 189: 183-193.
65. Luisetti M, Kadija Z, Mariani F, Rodi G, Campo I, Trapnell BC: Therapy options in pulmonary alveolar proteinosis. Ther Adv Respir Dis 2010; 4: 239-248.
66. Suzuki T, Sakagami T, Young LR, Carey BC, Wood RE, Luisetti M, Wert SE, et al: Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med 2010; 182: 1292-1304.
67. Sarin VK, Gupta S, Leung TK, Taylor VE, Ohning BL, Whitsett JA, Fox JL: Biophysical and biological activity of a synthetic 8.7-kDa hydrophobic pulmonary surfactant protein SPB. Proc Natl Acad Sci USA 1990; 87: 2633-2637.
68. Baatz JE, Sarin V, Absolom DR, Baxter C, Whitsett JA: Effects of surfactant-associated protein SP-B synthetic analogs on the structure and surface activity of model membrane bilayers. Chem Phys Lipids 1991; 60: 163-178.
69. Cochrane CG, Revak SD, Merritt TA, Heldt GP, Hallman M, Cunningham MD, Easa D, Pramanik A, Edwards DK, Alberts MS: The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 404-410.
70. Cochrane CG: Surfactant protein B and mimic peptides in the function of pulmonary surfactant. FEBS Lett 1998; 430: 424;disc 425.
71. Speer CP, Sweet DG, Halliday HL: Surfactant therapy: past, present and future. Early Hum Dev 2013; 89:S22-S24.
72. Seehase M, Collins JJ, Kuypers E, Jellema RK, Ophelders DR, Ospina OL, Perez-Gil J, Bianco F, Garzia R, Razzetti R, Kramer BW: New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs. PLoS One 2012; 7:e47631.